Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker AVXL, has announced plans to publish its fiscal 2026 first-quarter financial results on Monday, February 9, 2026.
The update was disclosed in a company statement dated February 3, 2026, from New York.
Company focus
Anavex describes itself as a clinical-stage biopharmaceutical firm working on the development of treatments for conditions affecting the central nervous system (CNS).
According to the company, its research and development efforts cover Alzheimer’s disease, Parkinson’s disease and schizophrenia.
It also lists neurodevelopmental and neurodegenerative disorders, as well as rare diseases, including Rett syndrome, among the areas it is targeting.
Upcoming financial update
The company said it will issue its financial results for the first quarter of fiscal 2026 on the specified date.
No further financial details were provided in the announcement.
Where the announcement was published
The information was shared on the company’s website, Anavex.com, and was referenced as published on February 7, 2026.